Search
Results: 10
Refractory lupus nephritis
Andreas Kronbichler, Biljana Brezina, Philipp Gauckler, Luis F Quintana, David RW Jayne
May 13, 2019
Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response...
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Antonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, Hans-Joachim Anders, Martin Aringer, Ingeborg Bajema, John Boletis, Eleni Frangou, Frederic A Houssiau, Jane Hollis, Adexandre Karras, Francesca Marchiori, Stephen D Marks, Gabriella Moroni, Marta Mosca, Ioannis Parodis, Manuel Praga, Matthias Schneider, Josef S Smolen, Vladimir Tesar, Maria Trachana, Ronald F van Vollenhoven, Alexandre E Voskuyl, YK Onno Teng, Bernadette van Leew, George Bertsias, David Jayne, Dimitrios T Boumpas
Nov 03, 2021
OBJECTIVE: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). METHODS: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a...
Lupus Nephritis Systemic Lupus Erythematosus Treatment Antirheumatic Agents Azathioprine Calcineurin Inhibitors Drug Therapy Combination Europe Glomerular Filtration Rate Glucocorticoids Humans Hydroxychloroquine Immunosuppressive Agents Kidney Failure Chronic Lupus Nephritis Mycophenolic Acid Proteinuria Societies Medical
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis
Rachel B Jones, Thomas F Hiemstra, Jose Ballarin, Daniel Engelbert Blockmans, Paul Brogan, Annette Bruchfeld, Maria C Cid, Karen Dahlsveen, Janak De Zoysa, Georgína Espigol-Frigolé, Peter Lanyon, Chen Au Peh, Vladimir Tesar, Augusto Vaglio, Michael Walsh, Dorothy Walsh, Giles Walters, Lorraine Harper, David Jayne, European Vasculitis Study Group (EUVAS)
Feb 06, 2019
OBJECTIVES: Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections, malignancies and infertility. Mycophenolate mofetil...
ANCA-associated vasculitis cyclophosphamide induction therapy mycophenolate Randomised trial Adolescent Adult Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Azathioprine Child cyclophosphamide Female Humans Immunosuppressive Agents Induction Chemotherapy Male Mycophenolic Acid Recurrence Treatment Outcome
Elicitation of expert prior opinion
Lisa V Hampson, John Whitehead, Despina Eleftheriou, Catrin Tudur-Smith, Rachel Jones, David Jayne, Helen Hickey, Michael W Beresford, Claudia Bracaglia, Afonso Caldas, Rolando Cimaz, Joke Dehoorne, Pavla Dolezalova, Mark Friswell, Marija Jelusic, Stephen D Marks, Neil Martin, Anne-Marie McMahon, Joachim Peitz, Annet van Royen-Kerkhof, Oguz Soylemezoglu, Paul A Brogan
Nov 24, 2020
OBJECTIVES: Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian methodology can be used to maximise what is learnt from clinical trials in these circumstances. We elicited expert prior...
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis
Thomas F Hiemstra, Michael Walsh, Alfred Mahr, Caroline O Savage, Kirsten de Groot, Lorraine Harper, Thomas Hauser, Irmgard Neumann, Vladimir Tesar, Karl-Martin Wissing, Christian Pagnoux, Wilhelm Schmitt, David RW Jayne, European Vasculitis Study Group (EUVAS)
Aug 05, 2019
CONTEXT: Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are limited by partial efficacy and toxicity. OBJECTIVE: To compare the effects of mycophenolate mofetil...
SARS-COV-2 vaccine responses in renal patient populations.
Rona M Smith, Daniel J Cooper, Rainer Doffinger, Hannah Stacey, Abdulrahman Al-Mohammad, Ian Goodfellow, Stephen Baker, Sara Lear, Myra Hosmilo, Nicholas Pritchard, Nicholas Torpey, David Jayne, Vivien Yiu, Anil Chalisey, Jacinta Lee, Enric Vilnar, Chee Kay Cheung, Rachel B Jones
Jun 07, 2022
BACKGROUND: Dialysis patients and immunosuppressed renal patients are at increased risk of COVID-19 and were excluded from vaccine trials. We conducted a prospective multicentre study to assess SARS-CoV-2 vaccine antibody...
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Paul A Brogan, Barbara Arch, Helen Hickey, Jordi Anton, Este Iglesias, Eileen Baildam, Kamran Mahmood, Gavin Cleary, Elena Moraitis, Charalampia Papadopoulou, Michael W Beresford, Phil Riley, Selcan Demir, Seza Ozen, Giovanna Culeddu, Dyfrig A Hughes, Pavla Dolezalova, Lisa V Hampson, John Whitehead, David Jayne, Nicola Ruperto, Catrin Tudur-Smith, Despina Eleftheriou
Apr 19, 2021
OBJECTIVE: Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was...
Influence of race/ethnicity on response to lupus nephritis treatment
David Isenberg, Gerald B Appel, Gabriel Contreras, Mary A Dooley, Ellen M Ginzler, David Jayne, Jorge Sánchez-Guerrero, David Wofsy, Xueqing Yu, Neil Solomons
Nov 24, 2020
OBJECTIVE: To compare the efficacy and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as induction treatment for lupus nephritis (LN), by race, ethnicity and geographical region. METHODS: A total of...
In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes.
Mycophenolic acid (MPA) is an active metabolite of mycophenolate mofetil, a new immunosuppressive drug effective in the treatment of canine autoimmune diseases. The impact of MPA on immunity is ambiguous and its influence on the...
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
George K Bertsias, Maria Tektonidou, Zahir Amoura, Martin Aringer, Ingeborg Bajema, Jo HM Berden, John Boletis, Ricard Cervera, Thomas Dörner, Andrea Doria, Franco Ferrario, Jürgen Floege, Frederic A Houssiau, John PA Ioannidis, David A Isenberg, Cees GM Kallenberg, Liz Lightstone, Stephen D Marks, Alberto Martini, Gabriela Moroni, Irmgard Neumann, Manuel Praga, Matthias Schneider, Argyre Starra, Vladimir Tesar, Carlos Vasconcelos, Ronald F van Vollenhoven, Helena Zakharova, Marion Haubitz, Caroline Gordon, David Jayne, Dimitrios T Boumpas, European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
Nov 24, 2020
OBJECTIVES: To develop recommendations for the management of adult and paediatric lupus nephritis (LN). METHODS: The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to...